$SEM

ORTENZIO ROBERT A sold (to issuer) $4.6M of SEM (indirect holdings)

ORTENZIO ROBERT A (EXECUTIVE CHAIRMAN) sold (to issuer) 279,000 indirectly-held shares of SELECT MEDICAL HOLDINGS CORP (SEM) at $16.50 ($4.60M total) on 2026-06-30.

Original reporting
SEC EDGAR · ORTENZIO ROBERT A
Published Jul 1, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 6:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SEM
Neutral
medium confidence
Mentioned
$SEM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SEMNeutralLow
01

Why it matters

The newest fact is the specific insider sale: 279,000 shares at $16.50/share totaling $4.6035M, with holdings after transaction reported as 0 shares (indirect).

02

Market read

Traders may briefly reassess sentiment around SEM due to an executive chairman sale, but the issuer-sale structure suggests limited fundamental signal.

03

What to watch

No 10b5-1 plan is cited, so traders may over-interpret; also the filing date can lag the actual transaction, limiting immediate catalyst value.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed July 1, 2026 (transaction dated June 30).

Background

The article is an SEC Form 4 insider transaction disclosure for Select Medical Holdings Corp (SEM).

Company-level read

Ticker impact

$SEMNeutralMedium confidence
Context

Select Medical Holdings insider Form 4 shows Robert A. Ortenzio sold 279,000 shares to the issuer for $4.6M on 2026-06-30.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a primary-source Form 4 with transaction size ($4.6M) and role (executive chairman), but it specifies sale to issuer and no 10b5-1 plan, which reduces interpretability for directional signaling.

Market effects

Minimal; insider transaction does not change Select Medical’s operating outlook or sector fundamentals.

None.

None.

Counterpoint

Because the sale is to the issuer (often tied to buyback mechanics), it may reflect liquidity/plan execution rather than bearish conviction.

Key entities

  • SELECT MEDICAL HOLDINGS CORP

    Public company subject of the Form 4 insider transaction disclosure.

  • ORTENZIO ROBERT A

    Executive Chairman and 10% owner; reported sale to issuer via Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QXOHighAI 9/10

Are KORE, SEM, BLD, QXO Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC said it is investigating potential securities-law or fiduciary-duty issues in deals involving KORE Group Holdings’ sale to Searchlight Capital Partners and Abry Partners for $9.25/share, Select Medical’s sale for $16.50/share, and TopBuild’s proposed acquisition by QXO. The firm also flagged QXO’s merger with TopBuild and said it may seek higher consideration or additional disclosures.

$QXOHighAI 9/10

Are KORE, SEM, BLD, QXO Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC said it is investigating potential securities-law violations and fiduciary-duty breaches involving KORE Group Holdings’ sale to Searchlight Capital Partners and Abry Partners for $9.25/share, Select Medical’s sale to a consortium led by its executives/directors for $16.50/share, and TopBuild’s proposed deal with QXO. TopBuild holders would choose $505 cash or 20.2 QXO shares per share.